Bevacizumab + Chemo Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer

Share this content:

(CHICAGO, IL) — In women with platinum-resistant ovarian cancer, bevacizumab plus chemotherapy doubled progression-free survival (PFS) compared with chemotherapy alone, according to the results of the first randomized phase 3 trial to show a benefit with a targeted therapy and improved outcome with a combination vs. monotherapy presented at the 2012 American Society of Clinical Oncology Annual Meeting.

“These results are very significant because the addition of bevacizumab offers a new treatment option for the 20% of women who have primary platinum-resistant disease, as well as those whose disease later becomes platinum-resistant,” said lead study author Eric Pujade-Lauraine, MD, PhD, professor, Université de Paris Descartes, France, and head of the Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), a clinical trials cooperative group based in France. “For the first time in platinum-resistant ovarian cancer, we have been able to significantly improve progression-free survival with a combination therapy.”

Between October 2009 and April 2011, the AURELIA trial randomly assigned 361 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that had progressed ≤6 months after ≥4 cycles of platinum-based therapy to one of three standard chemotherapy agents normally offered in this setting: weekly paclitaxel (n=115), topotecan (n=120) or liposomal pegylated doxorubicin (n=126) alone or with bevacizumab 15mg/kg every 3 weeks (depending on chemotherapy). Investigators selected chemotherapy based on each patient's previous experience with the drugs. At disease progression, patients in the chemotherapy-alone arm could cross over to bevacizumab monotherapy.

Median PFS, the primary endpoint, was 6.7 months in the bevacizumab arm vs. 3.4 months in the chemotherapy-alone arm (HR, 0.48; log-rank P<0.001). Objective response rate was 12.6% in the chemotherapy alone arm and 30.9% in the bevacizumab arm (P=0.001).

Adverse events were higher in the bevacizumab group. These included grade 2 or greater hypertension (20% vs. 7%), proteinuria (11% vs. 0.6%), gastrointestinal perforations (2% vs. 0), and fistula or abscesses (2% vs. 0). For adverse events grade 3 or greater, study arms were equivalent.

Strict patient selection — based on the absence of history of bowel obstruction/abdominal fistula or clinical/radiological evidence of rectosigmoid involvement — helped limit incidence of adverse events due to bevacizumab, Dr. Pujade-Lauraine said.

AURELIA is the first randomized phase 3 trial in platinum-resistant chemotherapy to demonstrate benefit with biologic therapy; bevacizumab combined with chemotherapy should be considered a new standard option in platinum-resistant ovarian cancer.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs